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BACKGROUND: Fever is one of the leading causes of con-
sultation in the pediatric emergency department for
patients under the age of 3 years. Distinguishing be-
tween bacterial and viral infections etiologies in febrile
patients remains challenging. We hypothesized that spe-
cific host biomarkers for viral infections, such as type I-
interferon (IFN), could help clinicians’ decisions and
limit antibiotic overuse.
METHODS: Paxgene tubes and serum were collected
from febrile children (n¼ 101), age from 7 days to
36months, with proven viral or bacterial infections, be-
ing treated at pediatric emergency departments in
France. We assessed the performance of an IFN signa-
ture, which was based on quantification of expression of
IFN-stimulated genes using the NanostringV
R
technology
and plasma IFN-a quantified by digital ELISA
technology.
RESULTS: Serum concentrations of IFN-a were below
the quantification threshold (30 fg/mL) for 2% (1/46)
of children with proven viral infections and for 71%
(39/55) of children with bacterial infections
(P< 0.001). IFN-a concentrations and IFN score were
significantly higher in viral compared to bacterial infec-
tion (P< 0.001). There was a strong correlation be-
tween serum IFN-a concentrations and IFN score
(p-pearson¼ 0.83). Both serum IFN-a concentration
and IFN score robustly discriminated (Area Under the
Curve >0.91 for both) between viral and bacterial infec-
tion in febrile children, compared to C-reactive protein
(0.83).
CONCLUSIONS: IFN-a is increased in blood of febrile
infants with viral infections. The discriminative perfor-
mance of IFN-a femtomolar concentrations as well as
blood transcriptional signatures could show a diagnostic
benefit and potentially limit antibiotic overuse.
CLINICAL TRIALS REGISTRATION: clinicaltrials.gov
(NCT03163628).
Type I interferons (IFNs) are a group of cytokines that
are involved in the innate antiviral response. A chronic
exposure to these cytokines is also linked to the patho-
physiology of a group of autoimmune diseases called
type I interferonopathies (1, 2). Because IFNs are se-
creted at very low concentrations (femtomolar) during
disease course, detection of type I IFN in patients
remains challenging and has led several groups to pro-
pose an alternative strategy for the monitoring of this
group of cytokines. Based on the quantification of ex-
pression of IFN-stimulated genes (ISGs), blood tran-
scriptional signatures (IFN signatures) provide an
indirect estimate of the exposure of cells to type I IFN
and are being proposed for the screening of autoim-
mune diseases (3). In addition, the recent development
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of digital ELISA (single molecular array, Simoa) allows
an analytically sensitive measurement of type I IFN
molecules in the sera of patients.
In children, the diagnosis of viral versus invasive
bacterial infection is challenging since the main symp-
toms at onset are often similar and restricted to fever.
Misdiagnosis is responsible for inappropriate antibiotic
prescription, contributing to the emergence of multi-
drug resistant bacteria. Thus, we hypothesized that type
I IFN, the key cytokine of antiviral response, may repre-
sent a new early biomarker of viral infection that could
eventually help clinicians limit antibiotic overuse. The
aim of this proof-of-concept study was to assess the per-
formance of plasma IFN-a and IFN score in distin-
guishing documented viral and bacterial infections in a
prospective cohort of children attending pediatric emer-
gency departments for fever.
Materials and methods
PARTICIPANTS
This was an ancillary study of the prospective multicen-
ter protocol ANTOINE (NCT03163628) (Fig. 1).
Patients were included prospectively in this multicenter
study from June 2017 to June 2019 (NCT03163628).
The ANTOINE study was registered to the French
National Data Protection Agency under the number 17-
168 and was approved by an ethics committee for bio-
medical research in May 2017 (Comite´ de Protection des
Personnes Sud Me´diterrane´e II) under the number 217
R18. For each participant, written informed consent
was obtained from parents or legal guardians for partici-
pation of the febrile children in the ANTOINE study.
An additional specific written consent was needed to al-
low the participation of the present ancillary study.
Inclusion and exclusion criteria are detailed in Table 1.
Febrile children aged from 7 days to 36months at-
tending a pediatric emergency department for a suspi-
cion of infection were recruited prospectively in three
different hospitals based in Lyon, Villefranche sur
Saone, and Colombes in France. Inclusion criteria were
fever for more than 6 h (temperature 38 C between
7 days and 3months and 38.5 C between 3months
and 36months) for which the physician prescribed veni-
puncture for suspected severe bacterial infection before
any antibiotic treatment. For this study, PaxgeneVR tubes
and serum were collected together with clinical blood
tests.
Concomitantly, blood samples from 10 healthy vol-
unteers were obtained from the national blood service
(Etablissement Franc¸ais du Sang, Lyon, France). We
used the Etablissement Franc¸ais du Sang standardized
procedures for blood donation and followed provisions
of articles R.1243–49 and the French public health
code to obtain written non-opposition to the use of
donated blood for research purposes from healthy vol-
unteers. The blood donors’ personal data were deidenti-
fied before transfer to our research laboratory. We
obtained the favorable notice of the local ethics commit-
tee (Comite´ de Protection des Personnes Sud-Est II,
Baˆtiment Pinel, 59 Boulevard Pinel, 69 500 Bron) and
acceptance from the French ministry of research
(Ministe`re de l’Enseignement supe´rieur, de la Recherche
et de l’Innovation, DC-2008-64) for the handling and
conservation of these samples.
In addition, a pediatric disease control population
(n¼ 9) with no infection nor characterized type I
Interferonopathies was also selected among patients at-
tending consultations at the National Referee Centre for
Rheumatic and AutoImmune and Systemic diseases in
childrEn (RAISE). This assessment was done on a rou-
tine basis in the referee center. This study was approved
by the Hospices Civils de Lyon ethics committee under
the number 2013-011B. The characteristics of pediatric
control population are available in Supplemental
Table 1.
Fig. 1. Flow diagram of study population. Recruitment and
flow of children presenting at the hospital with fever. An
additional specific written consent was needed to allow the
participation of the present ancillary study. The infections
were proven on the basis of a definite identification of
pathogens using routine microbiology testing. Assignment
of patients to clinical groups was validated by consensus of
an independent adjudication committee.
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DIAGNOSTIC PROCESS
The ANTOINE study was designed to evaluate the per-
formance of several biomarkers in “real-life” conditions.
No other blood tests nor clinical investigation were per-
formed beyond those requested by the emergency physi-
cian caring for febrile children. All patients underwent
routine investigations as part of clinical care including
blood count, C-reactive protein (CRP), blood chemis-
tries, blood, stool and urine cultures, and cerebrospinal
fluid analysis where indicated. Chest radiographs were
undertaken as clinically indicated. Bacteria culture and
viral diagnostics using multiplex PCR were performed
by routine microbiological laboratories of each hospital.
For patients with suspicion of respiratory tract infec-
tions, specific PCRs targeting influenza virus or respira-
tory syncytial virus were performed systematically
during seasonal peak.
According to the routine microbiology results and
the clinical parameters recorded in a numerical clinical
record folder, we retained patients with proven viral
(n¼ 46) or bacterial (n¼ 55) infections for this study
(Table 2). The infections were proven on the basis of a
definite identification of pathogens using routine micro-
biology testing. Assignment of patients to clinical groups
was validated by consensus of an independent adjudica-
tion committee.
IFN-a AND IFN-c ASSAY
Serum IFN-a concentrations (fg/mL) were determined
by single molecule array (Simoa) using a commercial kit
for IFN-a quantification (QuanterixTM). The assay was
based on a 3-step protocol using an HD- 1 Analyzer
(Quanterix; (4, 5)). IFN-c concentrations were mea-
sured using the simple plex kit IFN-c assay with the
Ella platform (Protein simpleVC ), according to manufac-
turer’s instructions.
IFN SCORE ASSESSMENT
RNA was extracted from whole blood contained in
PaxgeneVR tubes (Kit PreAnalytix, QiagenVC ) and quanti-
fied by spectrophotometric assay (Nanodrop 2000,
Thermo ScientificTM). RNA integrity was then evalu-
ated by Agilent RNA microarray (Agilent
TechnologiesVC ). mRNA quantification of 6 ISGs (inter-
feron alpha inducible protein 27 (IFI27), interferon in-
duced protein 44 like (IFI44L), Interferon Induced Protein
With Tetratricopeptide Repeats 1 (IFIT1), ISG15
Ubiquitin Like Modifier (ISG15), Radical S-Adenosyl
Methionine Domain Containing 2 (RSAD2), Sialic Acid
Binding Ig Like Lectin 1 (SIGLEC1) and 3 housekeeping
genes (Actin Beta (ACTB), Hypoxanthine
Phosphoribosyltransferase 1 (HPRT1), RNA Polymerase II
Subunit A (POLR2A)), was performed using nanostring
technology (Nanostring TechnologiesVC ). Data standardi-
zation was obtained using the geometric mean of internal
control and housekeeping genes count number. Interferon
score was calculated as previously described (6).
STATISTICAL ANALYSIS
Non-parametric Mann-Whitney tests and Spearman’s
correlation were calculated for all parameters using R
software V3.6.1. A P-value <0.05 was considered statis-
tically significant.
Results
Serum concentrations of IFN-a were below the quanti-
fication threshold (30 fg/mL) for 2% (1/46) of children
with proven viral infections and for 71% (39/55) of
children with bacterial infections (P< 0.001). Median
[IQR] IFN-a concentrations were significantly higher in
viral (7856 [3096–62 305] fg/mL) compared to bacte-
rial infections (406 [68–3708] fg/mL, P< 0.001;
Table 1. Exclusion and inclusion criteria.
Inclusion criteria
Febrile children:
• Between 7 days and 3 months old: fever >38 C for more than 6 h (late neonatal fever suspected) for which the physi-
cian prescribed venipuncture
• Between 3 months and 36 months old: fever 38,5 C for more than 6 h and less than 7 days for which the physician
prescribed venipuncture for suspected severe bacterial infection
Patient with national health insurance
Consent form signed by at least one parent/legal guardian
Exclusion criteria
Children treated by antibiotherapy within the past 48 h
Children with congenital or acquired immunodeficiency syndrome or long-term immunosuppression treatment
Children vaccinated within previous 48 h by an inactivated vaccine or within previous 10 days for the MMR (measles,
mumps, and rubella) vaccines
Children with a chronic disease
Undergoing surgery within 7 days before inclusion
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Fig. 2A). Similarly, the IFN score was increased 30-fold
in viral infections compared to bacterial ones
(P< 0.001; Fig. 2B). Interestingly, no significant differ-
ence was observed between febrile children with bacte-
rial infections and healthy volunteers or control
pediatric population. There was a strong positive
correlation between serum IFN-a concentrations and
the IFN score (r-spearman [95%CI] 0.85 [0.76; 0.91],
Fig. 2C).
Analysis of the area under the curve [95%CI]
showed that both IFN-a serum concentration (0.930
[0.877; 0.983]) and IFN score (0.908 [0.845; 0.971])
robustly discriminated viral infections from bacterial
ones in febrile children (Fig. 3). To evaluate if IFN-a
could improve the diagnosis of febrile children attending
pediatric emergency departments, we assessed the per-
formance of this biomarker in combination with a clini-
cally validated test that is CRP quantification. The area
under the curve shown in Fig. 3 revealed that the ratio
of the concentrations of CRP and IFN-a strongly
improves the classification of these patients compared to
CRP alone (0.936 [0.888; 0.985] versus 0.829 [0.747;
0.910] respectively, Fig. 3).
In addition, knowing that ISG expression may also
be driven by Type II interferon, we then evaluated
whether serum IFN-c concentrations would correlate with
the IFN score. No significant difference was observed be-
tween IFN-c serum concentrations for children with viral
infections compared to those with bacterial infections
(Fig. 4A). Additionally, there was no relation between ISG
expression and Type II interferon circulating concentra-
tions (r-spearman 0.18 [-0.054; 0.407]; Fig. 4B).
Discussion
Biomarkers have become key tools during the clinical
decision-making process for clinicians dealing with
Fig. 2. Type I Interferon quantification in febrile children with proven viral or bacterial infection. A) IFN-a (fg/mL) measured by
digital ELISA (SIMOAVR ). B) IFN score as defined by a 6 interferon stimulated gene transcriptional signature quantified using
nanostring technology and obtained from Paxgene tubes from febrile infants with proven viral (n¼ 46) or bacterial (n¼ 55)
infections attending pediatric emergency departments or from healthy controls (n¼ 10) or from pediatric controls (n¼ 9). Limit
of quantification is indicated by the dotted lines. The IFN-a kit (QuanterixTM) used for this study detect IFN-a type 2.
C) Spearman correlation between IFN score and serum IFN-a concentrations. For Fig. 2A and 2B, the box-and-whisker plots rep-
resent the median and inter-quartile range; whiskers were calculated by the Tukey’s method. Mann-Whitney U test
***P<0.001. IFN (Interferon).
Fig. 3. Receiver operating characteristic curve of C-reactive
protein (CRP), IFN score, serum IFN-a, and CRP/IFN-a ratio
concentrations to discriminate between viral and bacterial
infections. Analysis performed from data shown in Fig. 2.
Mann-Whitney U test ***P<0.001 – IFN (interferon); CRP
(C-reactive protein).
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febrile children. In the pediatric emergency department,
CRP, procalcitonin (PCT), and white blood cell count
are probably the most used markers despite their poor
clinical performance in guiding antibiotic prescription
in such clinical settings (7). In combination with a bio-
marker specific for bacterial infections, a specific bio-
marker for viral infections could improve the
management of febrile children. Recent clinical studies
have shown that the combination of CRP or PCT with
myxovirus resistance protein 1, coded by the ISG mx1,
strongly improved both the clinical sensitivity and spe-
cificity for differentiating infectious etiology (8, 9).
Nevertheless, myxovirus resistance protein 1 is an intra-
cellular protein that prevents the quantification of this
protein in serum or plasma, the method currently used
for dosage of CRP or PCT in routine laboratories (10).
Here, we assessed by digital ELISA the performance
provided by the measurement of protein IFN-a
itself, which is secreted by immune cells after recogni-
tion of viruses and detectable in serum or plasma. This
preliminary study showed that IFN-a, at the protein
level, is increased in blood of febrile infants with viral
infections.
Moreover, the biomarkers performance reported in
this study have been evaluated in the ANTOINE clini-
cal trial performed in “real-life” conditions. In our co-
hort, only 15% of patients had a definite infection
based on the routine microbiology results and the clini-
cal parameters, in line with previous reports showing
that laboratory tests failed to identify a causative patho-
gen in over half of children with severe illness or fever,
leaving an important place for biomarkers to improve
the management of febrile children (11, 12). In our
study, the microbiological investigation was not exhaus-
tive for each patient, explaining probably the low preva-
lence of rhinoviruses in our cohort. Consequently, viral
co-infection was not investigated/reported in our cohort.
This could explain the high concentration of interferon
alpha observed for some patients with a documented
bacterial infection.
The alternative to IFN-a protein quantification,
represented by an IFN score measurement, was also
evaluated in this study. The results showed that this
ISG-based signature had the same diagnostic perfor-
mance than IFN-a protein quantification. Fast track
RNA analyses using NanostringVR or FilmArrayVR plat-
forms could thus be helpful in implementing this bio-
marker in routine use. Of note, in cases of viral
infections, the circulating IFN-a concentrations, as well
as the IFN scores reported herein, were of the same or-
der of magnitude as those observed in cases of autoim-
mune disease such as systemic lupus erythematosus
(13). Moreover, several recent studies suggest that IFN-
a could be a useful biomarker to monitor interferonop-
athy disease activity, to identify patients with high risk
of relapse, and to select the best candidates for anti-
IFNa treatment (5, 14, 15). Our results suggest that vi-
ral infections could interfere and possibly be responsible
Fig. 4. Type II Interferon quantification in febrile children with proven viral or bacterial infection. A) IFN-c (pg/mL) measured in
serum from febrile infants with proven viral (n¼ 46) or bacterial (n¼ 54) infections attending pediatric emergency departments
One patient with bacterial infection had insufficient blood volume and IFN-c measurement was not performed. Box-and-whisker
plots represent the median and inter-quartile range, whiskers calculated by the Tukey’s method. Mann-Whitney U test
***P<0.001. B) Spearman correlation between IFN score and serum IFN-c concentrations.
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for false positive diagnoses when the IFN score or IFN-
a protein is used for the screening and the monitoring
of autoimmune diseases.
Of note, recent published data demonstrated that,
in specific clinical diseases such as Mycobacterium tuber-
culosis infections, interferon-stimulating genes (ISG) ex-
pression was not mediated through plasma type I IFN
(16). However, in febrile infants, our results showed
that the expression of ISG was driven by IFN-a and not
by IFN-c.
According to the 68th World Health Assembly dec-
laration, it is urgent to find effective diagnostic tools to
guide optimal antibiotic use (17). Our study showed
that measurement of IFN-a femtomolar concentrations,
as well as the use of an IFN score, could offer new per-
spectives for improving diagnosis and limiting antibiotic
overuse in febrile infants. The performance of IFN-a
needs to be confirmed in a larger cohort of febrile chil-
dren with suspected and proven infections.
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online.
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